Nelson Lee1, Aeron C Hurt2,3. 1. Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada. 2. WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute, Melbourne, Australia. 3. University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute, Melbourne, Australia.
Abstract
PURPOSE OF REVIEW: Neuraminidase inhibitors (NAIs), including oseltamivir, zanamivir, and peramivir, is the main class of antiviral available for clinical use. As such, development of resistance toward these agents is of great clinical and public health concern. RECENT FINDINGS: At present, NAI resistance remains uncommon among the circulating viruses (oseltamivir <3.5%, zanamivir <1%). Resistance risk is slightly higher in A(H1N1) than A(H3N2) and B viruses. Resistance may emerge during drug exposure, particularly among young children (<5 years), the immunocompromised, and individuals receiving prophylactic regimens. H275Y A(H1N1) variant, showing high-level oseltamivir resistance, is capable of causing outbreaks. R294K A(H7N9) variant shows reduced inhibition across NAIs. Multi-NAI resistance has been reported in the immunocompromised. SUMMARY: These findings highlight the importance of continuous surveillance, and assessment of viral fitness and transmissibility of resistant virus strains. Detection can be challenging, especially in a mix of resistant and wild-type viruses. Recent advances in molecular techniques (e.g. targeted mutation PCR, iART, ddPCR, pyrosequencing, next-generation sequencing) have improved detection and our understanding of viral dynamics. Treatment options available for oseltamivir-resistant viruses are limited, and susceptibility testing of other NAIs may be required, but non-NAI antivirals (e.g. polymerase inhibitors) that are active against these resistant viruses are in late-stage clinical development.
PURPOSE OF REVIEW: Neuraminidase inhibitors (NAIs), including oseltamivir, zanamivir, and peramivir, is the main class of antiviral available for clinical use. As such, development of resistance toward these agents is of great clinical and public health concern. RECENT FINDINGS: At present, NAI resistance remains uncommon among the circulating viruses (oseltamivir <3.5%, zanamivir <1%). Resistance risk is slightly higher in A(H1N1) than A(H3N2) and B viruses. Resistance may emerge during drug exposure, particularly among young children (<5 years), the immunocompromised, and individuals receiving prophylactic regimens. H275Y A(H1N1) variant, showing high-level oseltamivir resistance, is capable of causing outbreaks. R294K A(H7N9) variant shows reduced inhibition across NAIs. Multi-NAI resistance has been reported in the immunocompromised. SUMMARY: These findings highlight the importance of continuous surveillance, and assessment of viral fitness and transmissibility of resistant virus strains. Detection can be challenging, especially in a mix of resistant and wild-type viruses. Recent advances in molecular techniques (e.g. targeted mutation PCR, iART, ddPCR, pyrosequencing, next-generation sequencing) have improved detection and our understanding of viral dynamics. Treatment options available for oseltamivir-resistant viruses are limited, and susceptibility testing of other NAIs may be required, but non-NAI antivirals (e.g. polymerase inhibitors) that are active against these resistant viruses are in late-stage clinical development.
Authors: Dominga Rogolino; Lieve Naesens; Jennifer Bartoli; Mauro Carcelli; Laura De Luca; Giorgio Pelosi; Ryjul W Stokes; Ria Van Berwaer; Serena Vittorio; Annelies Stevaert; Seth M Cohen Journal: Bioorg Chem Date: 2021-10-01 Impact factor: 5.275
Authors: Elena A Govorkova; Emi Takashita; Rod S Daniels; Seiichiro Fujisaki; Lance D Presser; Mira C Patel; Weijuan Huang; Angie Lackenby; Ha T Nguyen; Dmitriy Pereyaslov; Aine Rattigan; Sook Kwan Brown; Magdi Samaan; Kanta Subbarao; Sun Wong; Dayan Wang; Richard J Webby; Hui-Ling Yen; Wenqing Zhang; Adam Meijer; Larisa V Gubareva Journal: Antiviral Res Date: 2022-03-12 Impact factor: 10.103
Authors: S F Bottom-Tanzer; K Rybkina; J N Bell; C A Alabi; C Mathieu; M Lu; S Biswas; M Vasquez; M Porotto; J A Melero; V Más; A Moscona Journal: mBio Date: 2019-02-19 Impact factor: 7.867
Authors: Chiara Medaglia; Arnaud Charles-Antoine Zwygart; Paulo Jacob Silva; Samuel Constant; Song Huang; Francesco Stellacci; Caroline Tapparel Journal: Microorganisms Date: 2021-06-01
Authors: Pasquale Laise; Gideon Bosker; Xiaoyun Sun; Yao Shen; Eugene F Douglass; Charles Karan; Ronald B Realubit; Sergey Pampou; Andrea Califano; Mariano J Alvarez Journal: bioRxiv Date: 2020-05-17